RESEARCH PAPER

Normal values of nasal NO and exhaled NO in young Chinese people aged 9 – 22 years

Shaohua You a,b, Jing Zhang b, Yin Bai, Lingchao Ji, Hongtian Wang*

Department of Otolaryngology Head and Neck Surgery, People’s Liberation Army General Hospital, Beijing 100853, China

Received 31 January 2016
Available online 19 March 2016

KEYWORDS
Nitric oxide; Nasal cavity; Lower respiratory tract; Normal value; Healthy people

Abstract  Objective: To assess the normal levels of nasal nitric oxide (NNO) and fractional exhaled nitric oxide (FENO) in healthy Chinese young people, and to determine whether the obtained values were associated with age, sex, height, weight, BMI (body mass index) or BSA (body surface area).

Methods: One hundred and twenty healthy people were selected from a total of 436 Chinese young people based on their answers to a questionnaire. An electrochemical analyzer (NIOX MINO system) was used to measure NNO and FENO. The relationship between NNO, FENO and age, sex, height, weight, BMI, BSA was analyzed using SPSS software.

Results: The values of NNO were normal distributed (mean 273.5 ppb; SD 112.3). The values of FENO were non-normally (Skewed) distributed (median: 14.00 ppb; interquartile range: 7.00 ppb). The obtained NNO values were independent of age, sex, height, weight, BMI and BSA, but were positively correlated to lnFENO (FENO log base e); lnFENO values were also independent of age, height, weight, BMI and BSA, but correlated with NNO and sex.

Conclusions: NNO values positively correlate with lnFENO in healthy people and the levels of each may be predicted by the other. The results of this study are expected to serve as a reference for future studies in China.

Copyright © 2016 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

* Corresponding author. Tel.: +86 13911681469; fax: +86 10 68156974.
E-mail address: wht301@263.net (H. Wang). Peer review under responsibility of Chinese Medical Association.

a Shaohua You is now working in the Department of Anesthesiology.
b Shaohua You and Jing Zhang are co-first author and they contributed to the paper equally.

http://dx.doi.org/10.1016/j.wjorl.2016.02.004
2095-8811/Copyright © 2016 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/+).
Introduction

Since the discovery of its function as an endothelium-derived relaxing factor in 1987, nitric oxide (NO) has been further documented to be present in the exhaled air of rabbits, guinea pigs, and humans. Nasal nitric oxide (NNO) refers to NO measured in air aspirated from the nasal cavity. The main source of this gaseous molecule is the paranasal sinus epithelium. The physiological role of NNO is to modulate ciliary motility, and to serve as an aerocrine mediator that helps to maintain adequate ventilation perfusion matching in the lung and nasal cavity. NO can kill bacteria, viruses, fungi, and tumor cells at high concentrations. In addition, inflammatory factors can activate nitric oxide synthetase (NOS), which can lead to a rapid increase in NNO concentration. NNO was recommended in Europe as the preferred first-line test for Primary Ciliary Dyskinesia (PCD) prior to performing confirmatory diagnostic tests in 2009. Patients with severe nasal polyps have low levels of NNO, which increase markedly following therapy. In patients with allergic rhinitis, NNO levels tend to be high and decrease following treatment. High levels of NNO almost certainly rule out the presence of cystic fibrosis. FENO refers to NO measured in air exhaled from the lower airway. FENO is produced by the human lung and is present in exhaled breath. The measurement of FENO has been standardized for clinical use and has been implicated in the pathophysiology of lung diseases, including asthma. NO is usually measured by chemiluminescence or electrochemical analyzers, which are secure, non-invasive, repeatable, and feasible methods. The development of sensitive techniques for the instantaneous measurement and monitoring of NO concentrations in human airways has spurred many clinical studies focused on monitoring diseases and the effects of treatments.

Although some progress has been made, the use of NNO as a marker of upper airway diseases within clinical practice still needs to be developed. In contrast to FENO, there is no current consensus on the normal values of NNO. In China, there have only been two reports about normal NNO levels; however, they reported different and inconsistent results. Therefore, in this study, we aimed to assess the normal values of NNO and FENO in healthy young people in China, and to determine the factors that affect NNO and FENO levels.

Materials and methods

Subjects

In total, 436 Chinese young people (aged 9–22 years) recruited from one college and one middle school were invited to participate in this study. The inclusion criteria were: aged between 9 and 22 years and written consent from themselves or their parents. The subjects were first asked if they had experienced any nasal or lower respiratory symptoms, including itching, rhinorrhea, sneezing, obstruction, cough, wheezing, and asthma, in the last four weeks. Subjects experiencing any nasal or lower respiratory symptoms were excluded. The remaining subjects were then asked to fill out an extensive questionnaire, which included potential confounding factors (sex, age, height, weight, BMI, BSA) and the exclusion criteria: history of respiratory diseases including rhinitis, deviation of nasal septum, nasal polyps, sinusitis, asthma, cough, wheezing, chronic pharyngitis, systemic or nasal administration of medications within two weeks; consumption of caffeine-containing beverages such as coffee, tea or cola; consumption of foods rich in nitrogen such as sausage, various animal offal, lettuce, and spinach within 2 h; respiratory tract infection within two weeks; related history of nasal operation; physical exercise within two hours of NO measurement; active or passive smoking.

The Ethical Committee of the Chinese People's Liberation Army General Hospital (Beijing, China) approved the study protocol.

Methods

NNO and FENO measurements

NNO and FENO were measured online according to the NIOX MINO manual (Aerocrine AB, Solna, Sweden). NIOX MINO does require ambient NO measurement. The NO measurement unit was parts per billion (ppb). The NNO measurement range was 5–1700 ppb, and the FENO measurement range was 5–300 ppb. The machine automatically recorded and stored the FENO and NNO values.

The measurement of NNO: The subjects rested for at least 30 min before measurement. A NO-inert olive tip was blocked firmly against the right nostril and was connected to NIOX MINO through a sampling tube. The flow rate was 5 ml/s. Subjects were asked to breathe normally and then hold their breath for 45 s. The concentration of NNO was automatically calculated by the NIOX MINO system.

The measurement of FENO: The subjects rested for 15 min after NNO measurement. The subjects were then asked to stand and exhale to residual volume. A mouthpiece was then inserted, the patient inhaled to total lung capacity and then exhaled for 10 s at a constant flow rate of about 50 ml/s. The NIOX MINO automatically reported the detected FENO concentrations.

Statistical analysis

All data were entered into a computer twice by two individuals. A one-Sample Kolmogorov–Smirnov Test was performed to analyze the distribution of baseline variables, which were described as the mean ± standard deviation (SD). FENO values and age were non-normally distributed, and they were expressed as the median (interquartile range, IQR). Logarithmic transformations were performed for FENO values and expressed as lnFENO. Correlation was examined using the Pearson and Spearman correlation analysis, and linear regression analysis was used to derive the prediction rules for NNO and FENO values. A P < 0.05 was considered statistically significant. All statistical procedures were performed using SPSS software, version 13.0.
Results

In total, 436 Chinese young people (aged 8–22 years) were willing to participate in this study, including 200 males (45.9%) and 236 females (54.1%). Of these volunteers, 279 were excluded due to nasal or lower respiratory symptoms. An additional 37 people were excluded after the second, more detailed, questionnaire. In total, 120 (27.5%) subjects (aged 9–22, average age 15.1 years) satisfied our requirements, and were selected to undergo NNO and the FENO measurement (Fig. 1). Of these subjects, 49 were male (40.8%) and 71 were female (59.2%). The general characteristics of the participants and their NNO and FENO measurements are displayed in Table 1.

NNO values

NNO values were normally distributed [(273.50 ± 112.28) ppb, 95% CI, 253.20–293.80 ppb] with a 95% reference value range of 53.43–493.57 ppb, and an absolute range from 16 to 582 ppb. Correlation analysis revealed that the NNO values were independent of age, sex, height, weight, BMI and BSA. However, lnFENO values were correlated positively with NNO (r = 0.283, P = 0.002), Table 2.

FENO values

The FENO values were not normally distributed. The median FENO value was 14.00 ppb (IQR, 7.00 ppb). The maximum was 73 ppb and the minimum 5 ppb with a 95% reference value range (prediction interval) of 53.43–355.59 ppb. For example, if a girl’s NNO is 300 ppb, then the predicted FENO concentration would be 13.71 ppb (e^{2.084 + 0.001063650672482 × 300 + 0.2150389683607 × 1}). NNO can also be predicted from FENO values as follows: NNO = \frac{141.426 + 355.594 × lnFENO − 113.267 × lnFENO2 + 14.254 × lnFENO3}{2}. For example, if FENO = 20 ppb and lnFENO = 3, then the approximate NNO concentration would be 290.811 ppb (e^{-141.426 + 355.594 × 3 + 113.267 × 3^2 + 14.254 × 3^3}).

Discussion

The official ATS (American Thoracic Society) clinical practice guidelines for the interpretation of FENO levels for clinical applications was issued in 2012.6 However, standardization of measurements, the establishment of reference values, and reference equations for NNO have not yet been developed. The measurement of NNO as a non-invasive method will be of great value in the field of rhinology. Since its first description in 1993, more studies have focused on FENO rather than NNO. The few studies reporting NNO values were variable and do not agree with the official guidelines. Since its first description in 1993, more studies have focused on FENO rather than NNO. The few studies reporting NNO values were variable and do not agree with the official guidelines. Since its first description in 1993, more studies have focused on FENO rather than NNO. The few studies reporting NNO values were variable and do not agree with the official guidelines.
Normal values of nasal NO and exhaled NO

Table 3  Reported NNO levels in healthy people and association with other factors.

| Year | First author | Healthy people | NNO levels in ppb | NNO associated |
|------|--------------|----------------|-------------------|----------------|
| 2002 | Colantonio D | n = 20          | 740.9 ± 148.1     |                |
| 2003 | Wodehouse T  | n = 16          | 759 ± 145.8       |                |
| 2005 | Struben VM   | n = 340         | 449 ± 115         |                |
| 2007 | Stark H      | n = 18          | Winter 133.5 ± 29.7 |                |
|      |              | n = 17          | Summer 138.0 ± 47.6 |                |
|      |              | n = 21          | Autumn 121.0 ± 37.5 |                |
| 2008 | Dressel H    | n = 19          | 7 AM–9 AM: 1505 ± 113 | With age (<12 yrs), but not sex, passive smoking, or BMI |
|      |              |                | 11 AM–1 PM: 1736 ± 109 |                |
|      |              |                | 1 PM–3 PM: 1730 ± 105 |                |
|      |              |                | 3 PM–5 PM: 1740 ± 95 |                |
|      |              |                | 5 PM–7PM: 1670 ± 103 |                |
|      |              |                | 11 AM–1 PM: 1736 ± 109 |                |
| 2009 | Zhang L      | n = 80          | 819 ± 211         | With age and gender, but not height or BMI |
| 2010 | Williamson PA | n = 41          | 878.1 (807.0–955.6) ppb | Without age, sex |
| 2010 | Kramer ME    | n = 11          | 1380 (988–2097)   |                |
| 2010 | Piacentini GL | n = 43          | 396.9 ± 25.0      | With age and weight, but not gender, height, or BMI |
| 2011 | Zhou H       | n = 35          | 303 ± 90          |                |
| 2011 | Marthin JK   | n = 52          | 534 ± 30          |                |
| 2012 | Leng YC      | n = 182         | 79 ± 35           |                |
| 2012 | Lee KJ       | n = 34          | 276 ± 88          |                |
| 2012 | Irander K    | n = 7           | 79 ± 33           |                |
| 2013 | Marthin JK   | n = 21          | MINO5, TB (nVC): 340 ± 23 | No relationship with age, gender, height, BMI, measure time, or right-left side |
|      |              | n = 21          | MINO2, TB (nVC): 752 ± 59 |                |
|      |              | n = 8           | NIOX MINO5, BH (VC): 603 ± 42 |                |
|      |              | n = 21          | NIOX FLEX, TB (nVC): 486 ± 34 |                |
|      |              | n = 21          | CLD 88 sp, TB (nVC): 499 ± 35 |                |
|      |              | n = 21          | NIOX FLEX, BH (VC): 890 ± 62 |                |
|      |              | n = 21          | CLD 88 sp1 (VC): 799 ± 57 |                |

BMI, body mass index; BSA, body surface area; MINO5: sampling rate 5 ml/s; MINO2: sampling rate 2 ml/s; TB: tidal breathing; BH: breathing hold; nVC: on-velum closure; VC: velum closure; NIOX (Aerocrine AB, Solna, Sweden): NIOX (hand-hold), NIOX MINO Nasal (hand-hold), NIOX FLEX (stationary); CLD 88 sp and CLD 88 sp1 (ECO MEDICSH AG, Duernten, Switzerland).
cohort demonstrated that after diagnosis, age, sex, and inhaled corticosteroids were taken into account, NNO was significantly associated with FENO (P = 0.02). Zhang L et al. found that NNO values were associated with age and gender, but not height or BMI. Leng G et al. came to a similar conclusion as that of the present study, namely that NNO levels in healthy people were independent of age, sex, height, weight, and BMI. However, Struben VM et al. found that NNO concentrations were not associated with sex, passive smoking, or BMI, but that in children aged <12 yrs, NNO correlated positively with age. Piacentini GL et al. reported that age and NNO concentration were significantly related in pre-school children and that children older than 6 years had levels of NNO that were about 100 ppb higher than those of children aged 3 or under. This can be explained by the accelerated pneumatization of developing paranasal sinuses that occurs during childhood. Similarly to other studies, we also found significantly higher FENO levels in males compared to females. The relationship between FENO and gender may be due to geometrical factors such as the total airway mucosal surface area and the airway caliber, both of which can affect FENO output. Interestingly, in our study, FENO did not correlate with the age, which is not consistent with the majority of previous studies (Table 4). Age has been found to be a strong factor that affects FENO concentration in children younger than 12 yrs. These inconsistent results may be explained by the fact that the majority of subjects were aged >12 yrs in this study, and that only 9.16% of subjects were aged <12 yrs. Struben VM et al. found that FENO correlated positively with age in children aged <12 yrs, but not in children aged >12 yrs, and that ambient NO was the only significant modifier in older children. The different outcomes of the various studies may be due to the following four possible explanations. First, individual differences depend on the sinus development, and sinus pneumatization is differs between all individuals. Second, some experts have found that the NNO levels of healthy subjects were lower in the morning than in the afternoon. Third, different equipment and different sampling flow rates may yield different results. Martin JK et al. found that using different instruments lead to different results. Measurements acquired at a sampling rate of 5 ml/s were superior to those acquired at 2 ml/s using the same instrument. Last, ambient NO levels may influence NNO levels. Although our instrument is unaffected by ambient NO, the instruments used in other studies may have been affected by it. High concentrations of ambient NO may reduce the gradient for NO diffusion from the nasal epithelium to the nasal cavity. Struben VM et al. found that the level of ambient NO (5–182 ppb) heavily influenced the measured levels of NNO in their study.

In conclusion, NNO values were independent of age, sex, height, weight, BMI, and BSA, but correlated positively with lnFENO. FENO values were also independent of age, height, weight, BMI and BSA. However, lnFENO values were correlated positively with NNO and sex. Although the relationship between NNO and lnFENO should be studied further, we hope that the results of this study may be helpful in the future clinical application of NNO.

Acknowledgements

The authors would like to thank the college and the middle school, and all the people who participated in our study. This project was supported by Clinical research fund (No. 2012FC-TSYS-2010) of the Chinese People’s Liberation Army General Hospital.

References

1. Gustafsson LE, Leone AM, Persson MG, Wiklund NP, Moncada S. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun. 1991; 181:852–857.
2. Barbato A, Frischer T, Kuehni CE, et al. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. *Eur Respir J.* 2009;34:1264–1276.

3. Carraro S, Cutrone C, Cardarelli C, Zanconato S, Baraldi E. Clinical application of nasal nitric oxide measurement. *Int J Immunopathol Pharmacol.* 2010;23:50–52.

4. Serrano C, Valero A, Picado C. Nasal nitric oxide. *Arch Bronconeumol.* 2004;40:222–230.

5. Walker WT, Liew A, Harris A, Cole J, Lucas JS. Upper and lower airway nitric oxide levels in primary ciliary dyskinesia, cystic fibrosis and asthma. *Respir Med.* 2013;107:380–386.

6. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med.* 2011;184:602–615.

7. Zhang L, Luo XR, Liu CY, Zhao Y, Han DM. Measurement of exhaled nitric oxide in healthy Chinese. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.* 2009;44:302–306.

8. Leng G, Li Z, Wang Q. Detection of exhaled nitric oxide of healthy in Nanjing. *Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.* 2012;26:769–771.

9. Stark H, Purokivi M, Kiviranta J, Randell J, Tukiainen H. Short-term and seasonal variations of exhaled and nasal NO in healthy subjects. *Respir Med.* 2007;101:265–271.

10. Dressel H, Bihler A, Jund F, et al. Diurnal variation of nasal nitric oxide levels in healthy subjects. *J Investig Allergol Clin Immunol.* 2008;18:316–317.

11. Marthin JK, Nielsen KG. Hand-held tidal breathing nasal nitric oxide measurement—a promising targeted case-finding tool for the diagnosis of primary ciliary dyskinesia. *PLoS One.* 2013;8:e57262.

12. Wodehouse T, Kharitonov SA, Mackay IS, Barnes PJ, Wilson R, Cole PJ. Nasal nitric oxide measurements for the screening of primary ciliary dyskinesia. *Eur Respir J.* 2003;21:43–47.

13. Marthin JK, Nielsen KG. Choice of nasal nitric oxide technique as first-line test for primary ciliary dyskinesia. *Eur Respir J.* 2011;37:559–565.

14. Bartley J, Ferguson W, Moody A, Wells AU, Kolbe J. Normal adult values, diurnal variation, and repeatability of nasal nitric oxide measurement. *Am J Rhinol.* 1999;13:401–405.

15. Williamson PA, Vaidyanathan S, Clearie K, Stewart M, Lipworth BJ. Relationship between fractional exhaled nitric oxide and nasal nitric oxide in airways disease. *Ann Allergy Asthma Immunol.* 2010;105:162–167.

16. Strubben VM, Wieringa MH, Mantingh CJ, et al. Nasal NO: normal values in children age 6 through to 17 years. *Eur Respir J.* 2005;26:453–457.

17. Piacentini GL, Bodini A, Peroni DG, et al. Nasal nitric oxide levels in healthy pre-school children. *Pediatr Allergy Immunol.* 2010;21:1139–1145.

18. Grasemann H, Storm van’s Gravesande K, Buscher R, Drazen JM, Ratjen F. Effects of sex and of gene variants in constitutive nitric oxide synthases on exhaled nitric oxide. *Am J Respir Crit Care Med.* 2003;167:1113–1116.

19. Colantonio D, Brouillette L, Parikh A, Scadding GK. Paradoxical low nasal nitric oxide in nasal polyposis. *Clin Exp Allergy.* 2002;32:698–701.

20. Naranj I, Ersu R, Wilson NM, Bush A. Nitric oxide in chronic airway inflammation in children: diagnostic use and pathophysiological significance. *Thorax.* 2002 Jul;57:586–589.

21. Kramer MF, Olzowy B, Bihler A, et al. Exhaled and nasal nitric oxide in laryngectomized patients. *BMC Pulm Med.* 2010;10:4.

22. Zhou H, Zou B, Hazucha M, Carson JL. Nasal nitric oxide and lifestyle exposure to tobacco smoke. *Ann Otol Rhinol Laryngol.* 2011;120:455–459.

23. Lee KJ, Cho SH, Lee SH, et al. Nasal and exhaled nitric oxide in allergic rhinitis. *Clin Exp Otorhinolaryngol.* 2012;5:228–233.

24. Irander K, Palm JP, Borres MP, Ghafoori B. Clara cell protein in nasal lavage fluid and nasal nitric oxide — biomarkers with anti-inflammatory properties in allergic rhinitis. *Clin Mol Allergy.* 2012;10:4.

25. Wong GW, Liu EK, Leung TF, et al. High levels and gender difference of exhaled nitric oxide in Chinese schoolchildren. *Clin Exp Allergy.* 2005;35:889–893.

26. Malmberg LP, Petäys T, Haatela T, et al. Exhaled nitric oxide in healthy nonatopic school-age children: determinants and height-adjusted reference values. *Pediatr Pulmonol.* 2006;41:635–642.

27. Kovesi T, Dales R. Exhaled nitric oxide and respiratory symptoms in a community sample of school aged children. *Pediatr Pulmonol.* 2008;43:1198–1205.

28. Hervás D, Milán JM, Garde J. Differences in exhaled nitric oxide in atopic children. *Allergol Immunopathol.* 2008;36:331–335.

29. Banovcin P, Jesenak M, Michnova Z, et al. Factors attributable to the level of exhaled nitric oxide in asthmatic children. *Eur J Med Res.* 2009;4:9–13.

30. Matsunaka K, Hirano T, Kawagama T, et al. Reference ranges for exhaled nitric oxide fraction in healthy Japanese adult population. *Allergol Int.* 2010;59:363–367.

31. Janahi I, Saadoon A, Tuffaha A, Panneerselvam B. Effects of age, gender, and environmental exposures on exhaled nitric oxide level in healthy 12 to 18 years Qatari children. *Ann Thorac Med.* 2012;7:98–103.

32. Zhang H, Shu L, Cai X, et al. Gender and age affect the levels of exhaled nitric oxide in healthy children. *Exp Ther Med.* 2013;5:1174–1178.

Edited by Jing Li